NM_177924.5:c.997C>G
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_177924.5(ASAH1):āc.997C>Gā(p.Arg333Gly) variant causes a missense change. The variant allele was found at a frequency of 0.0000204 in 1,614,174 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Consequence
NM_177924.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152176Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000557 AC: 14AN: 251460Hom.: 0 AF XY: 0.0000736 AC XY: 10AN XY: 135898
GnomAD4 exome AF: 0.0000198 AC: 29AN: 1461880Hom.: 0 Cov.: 32 AF XY: 0.0000289 AC XY: 21AN XY: 727238
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152294Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74448
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:3
- -
- -
- -
In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Arg333 amino acid residue in ASAH1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 27411168, 28733637). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ASAH1 protein function. ClinVar contains an entry for this variant (Variation ID: 585439). This variant is also known as p.Arg349Gly. This missense change has been observed in individuals with Farber disease (PMID: 24355074, 28733637). This variant is present in population databases (rs543697946, gnomAD 0.04%). This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 333 of the ASAH1 protein (p.Arg333Gly). -
Farber lipogranulomatosis Pathogenic:3
The ASAH1 c.997C>G p.Arg333Gly variant has been reported in heterozygous state in unrelated families affected with Farber lipogranulomatosis (Bashyam et. al., 2014; Yu. et al., 2018). Experimental studies have shown protein structural analysis on mutated amino acid sequence using HANSA and it is predicted that this change in sequence results in disruption in the conformation of the catalytic triad. (Bashyam et. al., 2014). This variant has been reported to the ClinVar database as Pathogenic, Likely Pathogenic and Variant of Uncertain Significance (VUS). It is reported with allele frequency of 0.006% in gnomAD database. The amino acid Arg at position 333 is changed to a Gly changing protein sequence and it might alter its composition and physico-chemical properties. The amino acid change p.Arg333Gly in ASAH1 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. -
Published data sheds additional light on variant c.997C>G suggesting the status be updated from uncertain significance to pathogenic. Four children from 3 unrelated families have been diagnosed with Farber disease associated with variant c.997C>G. Patient 1 discussed in Bashyam et al., 2014, doi: 10.1111/cge.12316, was diagnosed with Farber disease due to symptoms characteristic of Farber disease Type 1 (Gene Reviews; https://www.ncbi.nlm.nih.gov/books/NBK488189/). The child has compound heterozygous variants in the ASAH1 gene. Skin biopsy showed diffuse fibroblastic proliferation with diffuse chronic inflammatory cell infiltrates in the dermis with fat and foamy macrophages present in-between the fibroblasts which is characteristic of Farber disease. Protein structural analysis using HANSA was performed for the mutated amino acid sequence. It is predicted this change in sequence results in disruption in the conformation of the catalytic triad. Additionally, 2 siblings from a second unrelated family were were described in Bashyam et al., 2014, with Type 1 Farber disease. These sisters inherited the c.997C>G variant from their parents according to biparental segregation. Lastly, a fourth unrelated Farber disease patient was described in Cozma et al., 2017, DOI:10.1038/s41598-017-06604-2. In this patient, ceramide biomarker C26:0 was measured in samples from 10 Farber patients and 2 SMA-PME patients. It was demonstrated within this group that C26:0 Isoform 1 levels were significanly higher than the control group verifying the presence of Farber disease. -
- -
Abnormality of metabolism/homeostasis Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at